Skip to content

Evaluation of the efficacy and safety of inhaled magnesium sulfate in combination with standard treatment in Covid-19 patients

Evaluation of the efficacy and safety of inhaled magnesium sulfate in combination with standard treatment in Covid-19 patients: a clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20191211045691N1
Enrollment
100
Registered
2020-07-28
Start date
2020-07-30
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: includes 50 patients who receive magnesium sulfate inhaled (5 cc of a 20% injectable vial or 2 cc of a 50% injectable vial will be diluted by 50 cc distilled water

Sponsors

National Research Institute of Tuberculosis and Lung Diseases(NRITLD), Masih Daneshvari Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Minimum age 18 and maximum age 80 years Candidate for hospitalization ( o2sat24 ?? Pao2/Fio2<300) The first 24 hours or 48 hours of hospitalization Signing up the informed consent form

Exclusion criteria

Exclusion criteria: Patients with heart block Patients with myocardial injury

Design outcomes

Primary

MeasureTime frame
Improve respiratory symptoms including shortness of breath and cough. Timepoint: Days 1 to 5 and at the end of the first week. Method of measurement: Questionnaire.;Blood o2 saturation. Timepoint: Just before and 1 hour after prescribe medication. Method of measurement: Pulse oximetry device.

Secondary

MeasureTime frame
C-reactive protein. Timepoint: C-reactive protein is measured daily for days 1 to 5. Method of measurement: Measurement of C-reactive protein is performed by a laboratory sample of blood taken from the patient.;Total number of lymphocytes. Timepoint: The total number of lymphocytes is measured daily for days 1 to 5. Method of measurement: Measurement of The total number of lymphocytes is performed by a laboratory sample of blood taken from the patient.;D-dimer test. Timepoint: The D-dimer test is measured daily for days one to five. Method of measurement: The D-dimer test is performed with a blood sample taken from the patient by a laboratory.;Ferritin. Timepoint: Ferritin is measured daily for days 1 to 5. Method of measurement: Measurement of ferritin is performed by a laboratory sample of blood taken from the patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGuitti Pourdowlat

Shahid Beheshti University of Medical Sciences

pourdowlat_g@yahoo.com+98 21 2712 2000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 24, 2026